Turner, R. M.
de Koning, E. M.
Fontana, V.
Thompson, A.
Pirmohamed, M.
Funding for this research was provided by:
Health Education England Genomics Education Programme
Newton Fund
Academy of Medical Sciences
Medical Research Council
National Health Service NHS Chair of Pharmacogenetics
Article History
Received: 30 June 2020
Accepted: 27 October 2020
First Online: 25 November 2020
Ethics approval and consent to participate
: The protocol was approved by the Liverpool UK (adult) research Ethics Committee (07/H1005/117), site-specific approval was granted at all study sites, and written informed consent was ascertained from all study subjects in accordance with the Declaration of Helsinki.
: Not applicable.
: MP receives other research funding from various organisations including the EU Commission and NIHR. He has also received partnership funding for the following: MRC Clinical Pharmacology Training Scheme (co-funded by MRC and Roche, UCB, Eli Lilly and Novartis); a PhD studentship jointly funded by EPSRC and Astra Zeneca; and grant funding from Vistagen Therapeutics. He has also unrestricted educational grant support for the UKP harmacogenetics and Stratified Medicine Network from Bristol-Myers Squibb and UCB. He has developed an HLA genotyping panel with MC Diagnostics, but does not benefit financially from this. None of these of additional funding sources have been used for the current paper. The other authors declare that they have no competing interests.